Cargando…

Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2

Since ancient times, plants have been used for their medicinal properties. They provide us with many phytomolecules, which serve a synergistic function for human well-being. Along with anti-microbial, plants also possess anti-viral activities. In Western nations, about 50% of medicines were extracte...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Ravi, Bala, Rajni, Sindhu, Rakesh K., Zehravi, Mehrukh, Madaan, Reecha, Ramproshad, Sarker, Mondal, Banani, Dey, Abhijit, Rahman, Md. Habibur, Cavalu, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104170/
https://www.ncbi.nlm.nih.gov/pubmed/35564239
http://dx.doi.org/10.3390/nano12091530
_version_ 1784707729200250880
author Goyal, Ravi
Bala, Rajni
Sindhu, Rakesh K.
Zehravi, Mehrukh
Madaan, Reecha
Ramproshad, Sarker
Mondal, Banani
Dey, Abhijit
Rahman, Md. Habibur
Cavalu, Simona
author_facet Goyal, Ravi
Bala, Rajni
Sindhu, Rakesh K.
Zehravi, Mehrukh
Madaan, Reecha
Ramproshad, Sarker
Mondal, Banani
Dey, Abhijit
Rahman, Md. Habibur
Cavalu, Simona
author_sort Goyal, Ravi
collection PubMed
description Since ancient times, plants have been used for their medicinal properties. They provide us with many phytomolecules, which serve a synergistic function for human well-being. Along with anti-microbial, plants also possess anti-viral activities. In Western nations, about 50% of medicines were extracted from plants or their constituents. The spread and pandemic of viral diseases are becoming a major threat to public health and a burden on the financial prosperity of communities worldwide. In recent years, SARS-CoV-2 has made a dramatic lifestyle change. This has promoted scientists not to use synthetic anti-virals, such as protease inhibitors, nucleic acid analogs, and other anti-virals, but to study less toxic anti-viral phytomolecules. An emerging approach includes searching for eco-friendly therapeutic molecules to develop phytopharmaceuticals. This article briefly discusses numerous bioactive molecules that possess anti-viral properties, their mode of action, and possible applications in treating viral diseases, with a special focus on coronavirus and various nano-formulations used as a carrier for the delivery of phytoconstituents for improved bioavailability.
format Online
Article
Text
id pubmed-9104170
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91041702022-05-14 Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2 Goyal, Ravi Bala, Rajni Sindhu, Rakesh K. Zehravi, Mehrukh Madaan, Reecha Ramproshad, Sarker Mondal, Banani Dey, Abhijit Rahman, Md. Habibur Cavalu, Simona Nanomaterials (Basel) Review Since ancient times, plants have been used for their medicinal properties. They provide us with many phytomolecules, which serve a synergistic function for human well-being. Along with anti-microbial, plants also possess anti-viral activities. In Western nations, about 50% of medicines were extracted from plants or their constituents. The spread and pandemic of viral diseases are becoming a major threat to public health and a burden on the financial prosperity of communities worldwide. In recent years, SARS-CoV-2 has made a dramatic lifestyle change. This has promoted scientists not to use synthetic anti-virals, such as protease inhibitors, nucleic acid analogs, and other anti-virals, but to study less toxic anti-viral phytomolecules. An emerging approach includes searching for eco-friendly therapeutic molecules to develop phytopharmaceuticals. This article briefly discusses numerous bioactive molecules that possess anti-viral properties, their mode of action, and possible applications in treating viral diseases, with a special focus on coronavirus and various nano-formulations used as a carrier for the delivery of phytoconstituents for improved bioavailability. MDPI 2022-05-01 /pmc/articles/PMC9104170/ /pubmed/35564239 http://dx.doi.org/10.3390/nano12091530 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Goyal, Ravi
Bala, Rajni
Sindhu, Rakesh K.
Zehravi, Mehrukh
Madaan, Reecha
Ramproshad, Sarker
Mondal, Banani
Dey, Abhijit
Rahman, Md. Habibur
Cavalu, Simona
Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title_full Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title_fullStr Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title_full_unstemmed Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title_short Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
title_sort bioactive based nanocarriers for the treatment of viral infections and sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104170/
https://www.ncbi.nlm.nih.gov/pubmed/35564239
http://dx.doi.org/10.3390/nano12091530
work_keys_str_mv AT goyalravi bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT balarajni bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT sindhurakeshk bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT zehravimehrukh bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT madaanreecha bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT ramproshadsarker bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT mondalbanani bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT deyabhijit bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT rahmanmdhabibur bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2
AT cavalusimona bioactivebasednanocarriersforthetreatmentofviralinfectionsandsarscov2